Неконтрацептивные эффекты комбинированных оральных контрацептивов: преимущества и риски применения

1. Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010; 340: 927.
2. Прилепская В.Н., Межевитинова Е.А., Иванова Е.В., Сасунова Р.А. Контрацепция и возможности персонифицированного подхода к ее назначению в различные возрастные периоды женщины. Фарматека. 2014; 4: 6–10. / Prilepskaia V.N., Mezhevitinova E.A., Ivanova E.V., Sasunova R.A. Kontratseptsiia i vozmozhnosti personifitsirovannogo podkhoda k ee naznacheniiu v razlichnye vozrastnye periody zhenshchiny. Farmateka. 2014; 4: 6–10. [in Russian]
3. Vodstrcil LA, Hocking JS, Law M et al. Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. PLoSOne 2013; 8 (9): e73055.
4. Jarosik GP, Land CB, Duhon P et al. Acquisition of iron by Gardnerella vaginalis. Infect Immun 1998; 66 (10): 5041–7.
5. Sammon CJ, Nazareth I, Petersen I. Recording and treatment of premenstrual syndrome in UK general practice: a retrospective cohort study. BMJ Open 2016; 6 (3): e010244.
6. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586.
7. Lundin C, Danielsson KG, Bixo M et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology 2017; 76: 135–43.
8. Roberts SC, Little AC, Burriss RP et al. Partner choice, relationship satisfaction, and oral contraception: the congruency hypothesis. Psychol Sci 2014; 25 (7): 1497–503.
9. Zethraeus N, Dreber A, Ranehill E et al. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab 2016; 101 (11): 4046–53.
10. Azar-Ramos R. Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol 1989; 105: 1144–9.
11. Heikinheimo O, Fraser I. The current status of hormonal therapies for heavy menstrual bleeding. Best Pract Res Clin Obstet Gynaecol 2017; 40: 111–20.
12. Heikkinen S, Koskenvuo M, Malila N et al. Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. Cancer Causes Control 2016; 27 (2): 249–58.
13. Moroni RM, Martins WP, Dias SV et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest 2015; 79 (3): 145–52.
14. Davis AR, Westhoff C, O’Connell K et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized clinical trial. Obstet Gynecol 2005; 106: 97–104.
15. Momoeda M, Hayakawa M, Shimazaki Y et al. Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 2014; 6: 989–98.
16. Tafi E, Leone Roberti Maggiore U, Alessandri F et al. Advances in pharmacotherapy for treating endometriosis. Exp Opin Pharmacother 2015; 16: 2465–83.
17. Benagiano G, Guo SW, Bianchi P et al. Pharmacologic treatment of the ovarian endometrioma. Expert Opin Pharmacother 2016; 17 (15): 2019–31.
18. Vercellini P, De Matteis S, Somigliana E et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis Acta Obstet Gynecol Scand 2013; 92: 8–16.
19. Wu L, Wu Q, Liu L. Oral contraceptive pills for endometriosis after conservative surgery: a systematic review and meta-analysis. Gynecol Endocrinol 2013; 29 (10): 883–90.
20. Seracchioli R, Mabrouk M, Frascà C et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: A randomized controlled trial. Fertil Steril 2010; 93: 52–6.
21. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37–43.
22. Troncon JK, Neto OB, Nogueira AA, Rosae Silva JC. Continuous or cyclic contraceptives for endometriosis: a question still without an answer. Arch Gynecol Obstet 2015; 292: 481–2101.
23. Muzii L, Di Tucci C, Achilli C et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214: 203–11.
24. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2014; 4: CD006134.
25. Rodney JP, Sataloff RT. The Effects of Hormonal Contraception on the Voice: History of Its Evolution in the Literature. J Voice 2016; 30 (6): 726–30.
26. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20 (1): 76–105.
27. Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol 2014; 15 (3): 247–66.
28. Dokras A. Non contraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits. Fertil Steril 2016; 106 (7): 1572–9.
29. Adeniji AA, Essah PA, Nestler JE, Cheang KI. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome. J Womens Health (Larchmt) 2016; 25 (6): 638–45.
30. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; 1: CD003987.
31. Caprio M, Antelmi A, Chetrite G. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
32. Sitruk-Ware R, Nath A. Characteristics and metabolic effectsof estrogen and progestins containedin oral contraceptive pills. Pract Res Clin Endocrinol Metab 2013; 27: 13–24.
33. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014; 4: CD006133.
34. Roura E, Travier N, Waterboer T et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoSOne 2016; 11  (1): e0147029.
35. Havrilesky LJ, Gierisch JM, Moorman PG et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (FullRep) 2013; 212: 1–514.
36. Moorman PG, Havrilesky LJ, Gierisch JM et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31 (33): 4188–98.
37. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017. pii: S0002-9378(17)30179–5.
38. Wu L, Zhu J. Linear reduction in thyroid cancer risk by oral contraceptive use: a dose-response meta-analysis of prospective cohort studies. Hum Reprod 2015; 30 (9): 2234–40.
39. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16 (9): 1061–70. DOI: 10.1016/S1470-2045(15)00212-0. Epub 2015 Aug 4.
40. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303–14. DOI: 10.1016/S0140-6736(08)60167-1.
41. McLaughlin JR, Risch HA, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8 (1): 26–34.
42. The World Health Organization. Medical eligibility criteria for contraceptive use. Fifth edition. Contraception  2016; 94 (3): 193–4.
43. Tepper NK, Whiteman MK, Zapata LB et al. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception 2016; 94 (6): 630–40.
44. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107 (1): 43–51.
45. Stegeman BH, de Bastos M, Rosendaal FR et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298.
46. de Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
47. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013; 27: 25–34. 
48. Bird ST, Delaney JA, Etminan M et al. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol? J Thromb Haemost 2013; 11: 1059–68.
49. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
50. Ziller M, Ziller V, Haas G et al. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet 2014; 289: 413–9.
51. Sidney S, Cheetham TC, Connell FA et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87: 93–100.
52. Bateson D, Butcher BE, Donovan C et al. Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis. Aust Fam Physician 2016; 45 (1): 59–64.
53. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
54. Amoozegar F, Ronksley PE, Sauve R, Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front Neurol 2015; 6: 7.
55. Roach RE, Helmerhorst FM, Lijfering WM et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Data base Syst Rev 2015; 8: CD011054.
56. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016; 137: 11–6.
57. Инструкции по медицинскому применению препаратов Курантил® N25(ПN013897/01-280312), Курантил® N75 (ПN013899/01-280312). / Instrukcii po medicinskomu primeneniju preparatov Kurantil® N25(PN013897/01-280312), Kurantil® N75 (PN013899/01-280312). [in Russian]
58. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78–86.
59. Goda AE, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435–45.
60. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2014; 53 (3): 243–52.
61. Kowalska K, Milnerowicz H. Pro/antioxidant status in young healthy women using oral contraceptives. Environ Toxicol Pharmacol 2016; 43: 1–6.
62. Chen JT, Kotani K. Oral contraceptive therapy increases oxidative stress in pre-menopausal women. Int J Prev Med 2012; 3 (12): 893–6.
63. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015; 15 (9): 822–9.
64. Balakumar P, Nyo YH, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50.

________________________________________________

1. Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010; 340: 927.
2. Prilepskaia V.N., Mezhevitinova E.A., Ivanova E.V., Sasunova R.A. Kontratseptsiia i vozmozhnosti personifitsirovannogo podkhoda k ee naznacheniiu v razlichnye vozrastnye periody zhenshchiny. Farmateka. 2014; 4: 6–10. [in Russian]
3. Vodstrcil LA, Hocking JS, Law M et al. Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. PLoSOne 2013; 8 (9): e73055.
4. Jarosik GP, Land CB, Duhon P et al. Acquisition of iron by Gardnerella vaginalis. Infect Immun 1998; 66 (10): 5041–7.
5. Sammon CJ, Nazareth I, Petersen I. Recording and treatment of premenstrual syndrome in UK general practice: a retrospective cohort study. BMJ Open 2016; 6 (3): e010244.
6. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586.
7. Lundin C, Danielsson KG, Bixo M et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology 2017; 76: 135–43.
8. Roberts SC, Little AC, Burriss RP et al. Partner choice, relationship satisfaction, and oral contraception: the congruency hypothesis. Psychol Sci 2014; 25 (7): 1497–503.
9. Zethraeus N, Dreber A, Ranehill E et al. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab 2016; 101 (11): 4046–53.
10. Azar-Ramos R. Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol 1989; 105: 1144–9.
11. Heikinheimo O, Fraser I. The current status of hormonal therapies for heavy menstrual bleeding. Best Pract Res Clin Obstet Gynaecol 2017; 40: 111–20.
12. Heikkinen S, Koskenvuo M, Malila N et al. Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. Cancer Causes Control 2016; 27 (2): 249–58.
13. Moroni RM, Martins WP, Dias SV et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest 2015; 79 (3): 145–52.
14. Davis AR, Westhoff C, O’Connell K et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized clinical trial. Obstet Gynecol 2005; 106: 97–104.
15. Momoeda M, Hayakawa M, Shimazaki Y et al. Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 2014; 6: 989–98.
16. Tafi E, Leone Roberti Maggiore U, Alessandri F et al. Advances in pharmacotherapy for treating endometriosis. Exp Opin Pharmacother 2015; 16: 2465–83.
17. Benagiano G, Guo SW, Bianchi P et al. Pharmacologic treatment of the ovarian endometrioma. Expert Opin Pharmacother 2016; 17 (15): 2019–31.
18. Vercellini P, De Matteis S, Somigliana E et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis Acta Obstet Gynecol Scand 2013; 92: 8–16.
19. Wu L, Wu Q, Liu L. Oral contraceptive pills for endometriosis after conservative surgery: a systematic review and meta-analysis. Gynecol Endocrinol 2013; 29 (10): 883–90.
20. Seracchioli R, Mabrouk M, Frascà C et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: A randomized controlled trial. Fertil Steril 2010; 93: 52–6.
21. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37–43.
22. Troncon JK, Neto OB, Nogueira AA, Rosae Silva JC. Continuous or cyclic contraceptives for endometriosis: a question still without an answer. Arch Gynecol Obstet 2015; 292: 481–2101.
23. Muzii L, Di Tucci C, Achilli C et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214: 203–11.
24. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2014; 4: CD006134.
25. Rodney JP, Sataloff RT. The Effects of Hormonal Contraception on the Voice: History of Its Evolution in the Literature. J Voice 2016; 30 (6): 726–30.
26. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20 (1): 76–105.
27. Somani N, Turvy D. Hirsutism: an evidence-based treatment update. Am J Clin Dermatol 2014; 15 (3): 247–66.
28. Dokras A. Non contraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits. Fertil Steril 2016; 106 (7): 1572–9.
29. Adeniji AA, Essah PA, Nestler JE, Cheang KI. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome. J Womens Health (Larchmt) 2016; 25 (6): 638–45.
30. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; 1: CD003987.
31. Caprio M, Antelmi A, Chetrite G. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
32. Sitruk-Ware R, Nath A. Characteristics and metabolic effectsof estrogen and progestins containedin oral contraceptive pills. Pract Res Clin Endocrinol Metab 2013; 27: 13–24.
33. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014; 4: CD006133.
34. Roura E, Travier N, Waterboer T et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoSOne 2016; 11  (1): e0147029.
35. Havrilesky LJ, Gierisch JM, Moorman PG et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (FullRep) 2013; 212: 1–514.
36. Moorman PG, Havrilesky LJ, Gierisch JM et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31 (33): 4188–98.
37. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017. pii: S0002-9378(17)30179–5.
38. Wu L, Zhu J. Linear reduction in thyroid cancer risk by oral contraceptive use: a dose-response meta-analysis of prospective cohort studies. Hum Reprod 2015; 30 (9): 2234–40.
39. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16 (9): 1061–70. DOI: 10.1016/S1470-2045(15)00212-0. Epub 2015 Aug 4.
40. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303–14. DOI: 10.1016/S0140-6736(08)60167-1.
41. McLaughlin JR, Risch HA, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8 (1): 26–34.
42. The World Health Organization. Medical eligibility criteria for contraceptive use. Fifth edition. Contraception  2016; 94 (3): 193–4.
43. Tepper NK, Whiteman MK, Zapata LB et al. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception 2016; 94 (6): 630–40.
44. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107 (1): 43–51.
45. Stegeman BH, de Bastos M, Rosendaal FR et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298.
46. de Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
47. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013; 27: 25–34. 
48. Bird ST, Delaney JA, Etminan M et al. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol? J Thromb Haemost 2013; 11: 1059–68.
49. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
50. Ziller M, Ziller V, Haas G et al. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet 2014; 289: 413–9.
51. Sidney S, Cheetham TC, Connell FA et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87: 93–100.
52. Bateson D, Butcher BE, Donovan C et al. Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis. Aust Fam Physician 2016; 45 (1): 59–64.
53. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
54. Amoozegar F, Ronksley PE, Sauve R, Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front Neurol 2015; 6: 7.
55. Roach RE, Helmerhorst FM, Lijfering WM et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Data base Syst Rev 2015; 8: CD011054.
56. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016; 137: 11–6.
57. Instrukcii po medicinskomu primeneniju preparatov Kurantil® N25(PN013897/01-280312), Kurantil® N75 (PN013899/01-280312). [in Russian]
58. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78–86.
59. Goda AE, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435–45.
60. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2014; 53 (3): 243–52.
61. Kowalska K, Milnerowicz H. Pro/antioxidant status in young healthy women using oral contraceptives. Environ Toxicol Pharmacol 2016; 43: 1–6.
62. Chen JT, Kotani K. Oral contraceptive therapy increases oxidative stress in pre-menopausal women. Int J Prev Med 2012; 3 (12): 893–6.
63. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015; 15 (9): 822–9.
64. Balakumar P, Nyo YH, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50.

А.Л.Унанян*1, А.Д.Никонец1, Л.Н.Аминова2, В.А.Алимов2, Ю.В.Чушков1, А.В.Щукина3, Е.А.Кудрина1, Д.В.Бабурин1

1. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. Клиническая больница МЕДСИ. 125284, Россия, Москва, 2-й Боткинский пр., д. 5;
3. ГБУЗ «Городская поликлиника №68» Департамента здравоохранения г. Москвы. 119180, Россия, Москва, ул. Малая Якиманка, д. 22, стр. 1
*9603526@mail.ru

________________________________________________

A.L.Unanyan*1, A.D.Nikonets1, L.N.Aminova2, V.A.Alimov2, Yu.V.Chushkov1, A.V.Shchukina3, E.A.Kudrina1, D.V.Baburin1

1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. Clinical Hospital MEDSI. 125284, Russian Federation, Moscow, 2-i Botkinskiy pr., d. 5;
3. Сity Hospital №68 of the Department of Health of Moscow. 3119180, Russian Federation, Moscow, ul. Malaia Iakimanka, d. 22, str. 1
*9603526@mail.ru